Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value

Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 19th Feb, paid: 23rd Mar more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +10.9%

FINANCIAL BRIEF: For the nine months ended 30 September 2014, AstraZeneca plc revenues increased 3% to $19.41B. Net income decreased 50% to $1.55B. Revenues reflect United States segment increase of 62% to $7.48B, Western Europe segment increase of 55% to $4.93B. Net income was offset by Cost OF Sales - Restructuring Costs increase from $6M to $72M (expense), Distribution Costs increase of 1% to $236M (expense). Dividend per share remained flat at $0.90. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

Recent History
Latest interim period (ended 30th Sep '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: $74.4 (+3.61% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -3.2% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
28 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 5 4 14 3 5

Named Brokers and Analysts
Jefferies & Company, Inc. Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Savvas Neophytou , Redeye , Natixis Philippe Lanone Jean-Jacques Le Fur , Collins Stewart & Co , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgård , Davy , CA Cheuvreux , Macquarie Research , Societe Generale , Handelsbanken Capital Markets Peter Sehested , WestLB Equity Markets , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Kepler Cheuvreux Sheela Sharma, DPhil , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Matrix Corporate Capital LLP , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Directors: Pascal Soriot (CEO) 55, Marc Dunoyer (CFO) 61, Ruud Dobber (EVP) , Caroline Hempstead (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Briggs Morrison (EVP) , Menelas Pangalos (EVP) , David Smith (EVP) , Leif Johansson (NEC) 63, John Varley (NED) 58, Genevieve Berger (NED) 59, Ann Cairns (NED) 57, Marcus Wallenberg (NED) 58,

No. of Employees: 51,500 No. of Shareholders: 103,411

Last Annual December 31st, 2013
Last Interim September 30th, 2014
Shares in Issue 1,263,143,338
Free Float 1.26bn (99.7%)

Address 2 Kingdom Street Paddington, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 76048000
Contact Karl Hard (IR Contact Officer)
Auditors KPMG Audit PLC

AZN Share Price Performance AZN Quote
19.0  0.4%
Traded 11:49am · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Call
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Release
Friday 24th April, 2015
AstraZeneca PLC Annual Shareholders Meeting
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Release
Thursday 5th November, 2015
Q3 2015 AstraZeneca PLC Earnings Release
Friday 22nd April, 2016 (estimate)
AstraZeneca PLC Annual Shareholders Meeting

Recent ↓
Wednesday 14th January, 2015
AstraZeneca PLC at JPMorgan Healthcare Conference
Tuesday 18th November, 2014
AstraZeneca PLC Investor Day
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Call
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release
Sunday 28th September, 2014
AstraZeneca PLC European Society for Medical Oncology (ESMO) 2014 Analysts and Investors Briefing
Tuesday 23rd September, 2014
AstraZeneca PLC at EBD Group BioPharm America
Wednesday 13th August, 2014
Dividend For AZN.L
Wednesday 13th August, 2014
Dividend For AZN
Wednesday 13th August, 2014
Dividend For AZN.BA
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Release

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy AZN

Access AZN Analytics Now!